Durability of Response with Icotrokinra, a Targeted Oral Peptide, in Adults with Moderate-to-Severe Plaque Psoriasis: One-Year Results from the Phase 3, Placebo- and Active Comparator-Controlled Iconic-Advance 1 & Iconic-Advance 2 Trials
Recommended Citation
Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Reyes-Servin O, Edem BE, Cresswell K, Yang Y, Bissonnette R. Durability of Response with Icotrokinra, a Targeted Oral Peptide, in Adults with Moderate-to-Severe Plaque Psoriasis: One-Year Results from the Phase 3, Placebo- and Active Comparator-Controlled Iconic-Advance 1 & Iconic-Advance 2 Trials. J Am Acad Dermatol 2026; 95(1):AB170.
Document Type
Conference Proceeding
Publication Date
7-1-2026
Publication Title
J Am Acad Dermatol
Keywords
Dermatology
Abstract
Introduction: Among adults with moderate-to-severe plaque psoriasis in ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), the targeted oral peptide icotrokinra (ICO) demonstrated significantly higher rates of skin clearance vs placebo (PBO) at Week (W)16 and vs deucravacitinib (Deucra) at W16&W24, with adverse event (AE) rates similar to PBO and numerically lower than Deucra.1 Here, ICO findings through W52 of ICONIC-ADVANCE 1&2 are reported. Methods: ICONIC-ADVANCE 1&2 participants (pts) were randomized (2:1:2/4:1:4) to once-daily oral ICO 200mg, PBO (PBO→ICO at W16), or Deucra 6mg (Deucra→ICO at W24). Investigator’s Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) responses and AEs were assessed through W52. Results: In ICONIC-ADVANCE 1&2, 774/731 pts with moderate-to-severe psoriasis received ICO (311/322), PBO (156/82 [PBO→ICO=141/74]), or Deucra (307/327 [Deucra→ICO=283/301]). Skin clearance rates achieved with ICO through W24 of ICONIC-ADVANCE 1&2 (IGA0/1: 74/68%, PASI90: 66/65%, IGA0: 48/40%, PASI100: 41/33%) were maintained or increased through W52 (IGA0/1: 74/73%, PASI90: 69/71%, IGA0: 52/50%, PASI100: 49/48%). PBO→ICO pts achieved consistent rates of skin clearance at W52 (IGA 0/1: 75/80%, PASI 90: 71/74%, IGA0: 56/47%, PASI100: 50/43%). In Deucra→ICO pts, skin clearance rates at W24 (IGA0/1: 52/55%, PASI90: 41/43%, IGA0: 21/21%, PASI100: 16/16%) increased substantially after transitioning to ICO (W52 IGA 0/1: 75/79%, PASI 90: 71/77%, IGA0: 45/56%, PASI100: 42/51%). ICO safety through W52 was consistent with that observed through W16/W24. Conclusion: ICO provided robust and durable skin response rates through 1 year of treatment; skin clearance rates increased in Deucra-randomized pts after transitioning to ICO. No ICO safety signals were identified.
Volume
95
Issue
1
First Page
AB170
